News/ News/ R&D FDA unconvinced by Sanofi’s Zynquista in type 1 diabetes Phil Taylor Lexicon, Sanofi, Sotagliflozin, type 1 diabetes, Zynquista 0 Comment Sanofi’s hopes of getting its dual SGLT inhibitor sotagliflozin approved alongside insulin for type 1 diabetes in the Share X FDA unconvinced by Sanofi’s Zynquista in type 1 diabetes https://pharmaphorum.com/news/fda-unconvinced-by-sanofis-zynquista-in-type-1-diabetes/
Lexicon, Sanofi, Sotagliflozin, type 1 diabetes, Zynquista
0 Comment
